新生儿戒断综合征:诊断与治疗策略更新
本文综述了新生儿戒断综合征(NAS)的诊断与治疗策略。孕期处方阿片类及非法阿片类使用近年大幅增加,宫内长期药物暴露可致NAS,表现为生后数日内的急性多系统临床实体。管理首选非药物干预(无禁忌时促进母乳喂养),戒断症状严重时需药物治疗;Finnegan评分系统支持从起始到监测、减量及停药的药物治疗全程,但标准化药物治疗方案仍缺乏。
要点
- NAS管理首选非药物干预,无禁忌时促进母乳喂养。
- 戒断症状严重时需药物治疗,吗啡通常为一线药物。
- Finnegan评分系统支持药物治疗全程,但标准化方案仍缺乏。
核心结论
- NAS由母亲孕期长期使用合法或非法药物后胎儿经胎盘暴露、出生后突然中断所致,通常需延长住院并可能产生长期影响。
- NAS管理首选非药物干预,症状严重时需药物治疗,但标准化药物治疗方案仍缺乏。
研究设计与样本
- 本文为综述,未报告系统检索范围与样本量。
主要发现
- 孕期处方阿片类使用与非法阿片类滥用近年均大幅增加。
- NAS是生后数日内出现的急性多系统临床实体,其临床异质性由多因素交互作用所致,病理生理尚未完全阐明。
- 吗啡通常为NAS一线治疗药物;美沙酮为可选方案但安全性尚未完全明确。
- 苯巴比妥虽对胃肠道症状无效且药理学特征不理想,仍被确定为用于对阿片类无反应婴儿的二线药物。
- 丁丙诺啡与可乐定似乎有前景,但需进一步验证;NAS治疗的长期发育影响需更全面的纵向评估。
关键数值与推荐
- 非药物干预包括无禁忌时促进母乳喂养。
- Finnegan评分系统支持从药物治疗起始、监测至减量停药的全程。
- 吗啡通常为一线药物,美沙酮为可选方案,苯巴比妥为对阿片类无反应婴儿的二线药物。
临床怎么用
- 对疑似NAS婴儿先行非药物干预,无禁忌时促进母乳喂养。
- 采用Finnegan评分系统指导药物治疗的起始、监测、减量与停药。
- 症状严重时启动药物治疗,吗啡通常为一线,美沙酮为可选,苯巴比妥用于对阿片类无反应者。
- 丁丙诺啡与可乐定因证据尚不充分,使用需进一步验证。
局限性
- NAS病理生理尚未完全阐明,临床异质性由多因素交互作用所致。
- 标准化药物治疗方案仍缺乏。
- 美沙酮安全性尚未完全明确;丁丙诺啡与可乐定需进一步验证。
- NAS治疗的长期发育影响需更全面纵向评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Substance use among pregnant women is a major public health issue. Both prescription opioid use and illicit opioid abuse have increased dramatically in recent years. Prolonged in utero drug exposure may result in neonatal abstinence syndrome (NAS), an acute multisystemic clinical entity that occurs in the first days of life. This syndrome is caused by abrupt discontinuation of fetal exposure to licit or illicit drugs chronically consumed by the mother during pregnancy and transmitted to the fetus through the placenta. It usually requires prolonged hospitalization and may have long-term effects. The interplay of many factors contributes to its clinical heterogeneity, and its pathophysiology has not been fully unveiled. The first step in NAS management consists of nonpharmacologic interventions and includes promoting breastfeeding when not contraindicated. If withdrawal signs become severe, pharmacotherapy is needed. The Finnegan scoring system supports care providers across the pharmacotherapy process from initiation through the monitoring phase, until weaning and discontinuation. However, a standardized approach to pharmacotherapy is still lacking. Morphine is usually the first-line agent to treat NAS. Methadone is a valid option, but its safety profile is not completely known. Phenobarbital, despite its lack of effect on gastrointestinal symptoms and unfavorable pharmacologic features, has been identified as a second-line agent to be used in infants unresponsive to opiates. Although buprenorphine and clonidine seem promising, their use requires further validation. Long-term developmental effects of NAS therapy call for more-comprehensive, longitudinal assessments. In this article, key points for use of recommended therapies are outlined, and directions for future research are suggested.
引用
- Raffaeli G, Cavallaro G, Allegaert K, et al. Neonatal Abstinence Syndrome: Update on Diagnostic and Therapeutic Strategies. Pharmacotherapy. 2017. PMID: 28519244. doi:10.1002/phar.1954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。